Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker

Heart and Vessels

Volumn 28, Issue 1, 2013, Pages 7-11

  Ishibashi, Ken ^a   Kurisu, Satoshi ^a   Kato, Yasuko ^a   Mitsuba, Naoya ^a   Dohi, Yoshihiro ^a   Nishioka, Kenji ^a   Kihara, Yasuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Coronary artery disease; Fibrinolysis; Renin inhibitor

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; RENIN; STATIN (PROTEIN);

AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; FUMARATES; HUMANS; MALE; RENIN; TREATMENT OUTCOME;

EID: 84872606433     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-011-0204-7     Document Type: Article

References (23)

1. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins M (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327:669-677
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153
3. Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782-788
4. Hunt SA (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 46:e1-e82
5. Fujita M, Sasayama S, Terasaki F, Mitani S, Morimoto T, Yamazaki T, Hayashi D, Hohro T, Okada Y, Nagai R, JCAD Study Investigators (2010) Treatment effects of renin-angiotensin-system inhibitor and calcium channel blocker in patients with coronary artery narrowing (from the Japanese Coronary Artery Disease Study). Heart Vessels 25:453-459
6. Chen HQ, Tan HY, Yanq YW, Qiu L, Liu XQ (2010) Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome. Heart Vessels 25:77-81
7. Yusuf S, Teo K, Anderson C, Poque J, Dyal L, Copland I, Schumacher H, Dagenaris G, Sleight P (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174-1183
8. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T (2010) Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) trial. J Am Coll Cardiol 55:976-982
9. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111:1012-1018
10. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE (1998) Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32:965-971
11. Brown NJ, Agirbasli M, Vaughan DE (1999) Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34:285-290
12. Brown NJ, Kumar S, Painter CA, Vaughan DE (2002) ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 40:859-865
13. Hirschl MM, Bur A, Woisetschlaeger C, Derhaschnig U, Laggner AN (2007) Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients. J Clin Hypertens 9:430-435
14. Brown MJ, Mclnnes GT, Papst CC, Zhang J, MacDonald TM (2011) Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 377:312-320
15. One T, Sogabe M, Ogura M, Furusaki F (2003) Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma. Clin Chem 49:987-989
16. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, Sakata Y (2006) Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 84:398-405
17. Strauss MH, Hall AS (2006) Do angiotensin receptor blockers increase the risk of myocardial infarction? Circulation 114:838-854
18. Mooser V, Nussberger J, Juillerat L, Burier M, Waeber B, Bidiville J, Pauly N, Brunner HR (1990) Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 15:276-282
19. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enarapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100:1056-1064
20. Sato A, Saruta T (2003) Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16:781-788
21. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A (2007) Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8:190-198
22. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A (2007) Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49:276-284
23. Serebruany VL, Malinin A, Barsness G, Vahabi J, Atar D (2008) Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease. J Hum Hypertens 22:303-310